Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP platform trial in hospitalized acute respiratory tract infection
NL-OMON59912Phase 3Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tocilizumab in acute respiratory illness (ARI) and community-acquired pneumonia (CAP) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Survival and Recovery Trajectory, Day 90 all-cause mortality and 1 more. Started Feb 2016; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
acute respiratory illness (ARI)community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on NL-OMON59912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59912.